EMAIL THIS PAGE TO A FRIEND

The international journal of biochemistry & cell biology

Hyperosmolarity induced by high glucose promotes senescence in human glomerular mesangial cells.


PMID 25043688

Abstract

Hyperglycemia is involved in the diabetic complication of different organs and can elevate serum osmolarity. Here, we tested whether hyperosmolarity promoted by high glucose levels induces cellular senescence in renal cells. We treated Wistar rats with streptozotocin to induce diabetes or with consecutive daily injections of mannitol to increase serum osmolarity and analyzed p53 and p16 genes in renal cortex by immunohistochemistry. Both diabetic and mannitol treated rats showed a significant increase in serum osmolarity, without significant signs of renal dysfunction, but associated with increased staining for p53 and p16 in the renal cortex. An increase in p53 and p16 expression was also found in renal cortex slices and glomeruli isolated from healthy rats, which were later treated with 30 mM glucose or mannitol. Intracellular mechanisms involved were analyzed in cultured human glomerular mesangial cells treated with 30 mM glucose or mannitol. After treatments, cells showed increased p53, p21 and p16 expression and elevated senescence-associated β-galactosidase activity. Senescence was prevented when myo-inositol was added before treatment. High glucose or mannitol induced constitutive activation of Ras and ERK pathways which, in turn, were activated by oxidative stress. In summary, hyperosmolarity induced renal senescence, particularly in glomerular mesangial cells, increasing oxidative stress, which constitutively activated Ras-ERK 1/2 pathway. Cellular senescence could contribute to the organ dysfunction associated with diabetes.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

CKOZFN1001 CompoZr® Knockout ZFN Kit, human TP53 (NM_000546)
CKOZFN6906 CompoZr® Knockout ZFN Kit, Human D4S234E (NM_001040101)
CKOZFN2256 CompoZr® Knockout ZFN Kit, Human KRAS (NM_004985)
CKOZFN21892 CompoZr® Knockout ZFN Kit, Human TPT1 (NM_003295)
CKOZFND1001 CompoZr® Knockout ZFN Kit, ZFN plasmid only, Human TP53 (NM_000546)
CKOZFND6906 CompoZr® Knockout ZFN Kit, ZFN plasmid only, Human D4S234E (NM_001040101)
CKOZFND21892 CompoZr® Knockout ZFN Kit, ZFN plasmid only, Human TPT1 (NM_003295)
CKOZFND2256 CompoZr® Knockout ZFN Kit, ZFN plasmid only, Human KRAS (NM_004985)
EHU111621 MISSION® esiRNA, esiRNA human TPT1 (esiRNA1)
EHU114431
MISSION® esiRNA, esiRNA human KRAS (esiRNA1)
I5125
myo-Inositol, ≥99%
C6H12O6
I7508
myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture
C6H12O6
57570
myo-Inositol, for microbiology, ≥99.0%
C6H12O6
RES7034I-A7
myo-Inositol, PharmaGrade, meets FCC testing specifications, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.
C6H12O6
Y0000485
myo-Inositol, European Pharmacopoeia (EP) Reference Standard
C6H12O6
P6249 p53 human, recombinant, expressed in E. coli, buffered aqueous glycerol solution
P6374 p53 human, recombinant, expressed in baculovirus infected Sf21 cells